

# CITATION REPORT

List of articles citing

**A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?**

**DOI: 10.1111/dth.13383**

**Dermatologic Therapy, 2020, 33, e13383.**

**Source:** <https://exaly.com/paper-pdf/77561964/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
56	New-onset pustular psoriasis in the setting of infection causing coronavirus disease 2019. <i>JAAD Case Reports</i> , <b>2020</b> , 6, 1360-1362	1.4	13
55	Combating the Pandemic COVID-19: Clinical Trials, Therapies and Perspectives. <i>Frontiers in Molecular Biosciences</i> , <b>2020</b> , 7, 606393	5.6	17
54	Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1738-1748	4.5	17
53	The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. <i>Journal of Dermatological Treatment</i> , <b>2020</b> , 1-5	2.8	11
52	Hydroxychloroquine/oseltamivir. <i>Reactions Weekly</i> , <b>2020</b> , 1823, 191-191	0	
51	Pustular psoriasis exacerbated by COVID-19 in a patient with the history of psoriasis. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14462	2.2	9
50	National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 1704-1716	4.5	31
49	Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e14096	2.2	20
48	Dermatological diseases presented before COVID-19: Are patients with psoriasis and superficial fungal infections more vulnerable to the COVID-19?. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13509	2.2	20
47	Systemic immunobiological, immunosuppressant, and oncologic agents for the treatment of dermatologic diseases during the SARS-CoV-2 (COVID-19) pandemic emergency: A quick review for a quick consultation. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13537	2.2	2
46	The effect of the "stay-at-home" policy on requests for dermatology outpatient clinic visits after the COVID-19 outbreak. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13581	2.2	32
45	Covid-19 and exacerbation of psoriasis. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13632	2.2	29
44	Cutaneous manifestations and considerations in COVID-19 pandemic: A systematic review. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13986	2.2	57
43	Generalized pustular psoriasis following COVID-19. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14595	2.2	13
42	A systematic review on treatment-related mucocutaneous reactions in COVID-19 patients. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14662	2.2	15
41	COVID-19: The experience from Iran. <i>Clinics in Dermatology</i> , <b>2021</b> , 39, 23-32	3	5
40	Generalized exanthema due to hydroxychloroquine during COVID-19 prophylaxis. <i>International Journal of Clinical Practice</i> , <b>2021</b> , 75, e13793	2.9	

39	Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. <i>British Journal of Clinical Pharmacology</i> , <b>2021</b> , 87, 2111-2120	3.8	12
38	Toxicity of chloroquine and hydroxychloroquine following therapeutic use or overdose. <i>Clinical Toxicology</i> , <b>2021</b> , 59, 12-23	2.9	24
37	Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14806	2.2	3
36	Dermatology outpatient clinic outcomes after COVID-19 outbreak: What is new normal?. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14950	2.2	1
35	Biologics for Psoriasis during the COVID-19 Pandemic. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	5
34	Infection-provoked psoriasis: Induced or aggravated (Review). <i>Experimental and Therapeutic Medicine</i> , <b>2021</b> , 21, 567	2.1	5
33	How does COVID-19 impact psoriasis practice, prescription patterns, and healthcare delivery for psoriasis patients? A cross-sectional survey study. <i>Journal of Cosmetic Dermatology</i> , <b>2021</b> , 20, 1573-1579	2.5	1
32	Acrodermatitis Continua of Hallopeau Evolving into Generalized Pustular Psoriasis Following COVID-19: A Case Report of a Successful Treatment with Infliximab in Combination with Acitretin. <i>Biologics: Targets and Therapy</i> , <b>2021</b> , 15, 107-113	4.4	6
31	National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments. <i>Journal of the American Academy of Dermatology</i> , <b>2021</b> , 84, 1254-1268	4.5	42
30	Exacerbation of psoriasis following COVID-19 vaccination in a patient previously treated with PD-1 inhibitor. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e15055	2.2	4
29	New-onset guttate psoriasis secondary to COVID-19. <i>Clinical Case Reports (discontinued)</i> , <b>2021</b> , 9, e04542	2.7	1
28	Influence of SARS-CoV-2 Virus Infection on the Course of Psoriasis during Treatment with Biological Drugs. <i>Medicina (Lithuania)</i> , <b>2021</b> , 57,	3.1	0
27	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , <b>2021</b> , 11, 1889-1903	4.1	2
26	Influence of coronavirus infection on the course of psoriasis. <i>Meditinskiy Sovet</i> , <b>2021</b> , 332-338	0.4	0
25	On the importance of physicochemical parameters of copper and aminosilane functionalized mesoporous silica for hydroxychloroquine release. <i>Materials Science and Engineering C</i> , <b>2021</b> , 130, 112438	8.3	2
24	Dermatologic comorbidities of the patients with severe COVID-19: A case-control study. <i>Dermatologic Therapy</i> , <b>2021</b> , 34, e14731	2.2	2
23	Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment. <i>Journal of the American Academy of Dermatology</i> , <b>2020</b> , 83, 579-586	4.5	16
22	The explosion in scabies cases during COVID-19 pandemic. <i>Dermatologic Therapy</i> , <b>2020</b> , 33, e13662	2.2	10

21	COVID-19 related stress exacerbates common physical and mental pathologies and affects treatment (Review). <i>Experimental and Therapeutic Medicine</i> , <b>2020</b> , 20, 159-162	2.1	33
20	Impact of COVID-19 Pandemic on Dermatologists and Dermatology Practice. <i>Indian Dermatology Online Journal</i> , <b>2020</b> , 11, 328-332	0.9	13
19	Pustular psoriasis flare-up in a patient with COVID-19. <i>Journal of Cosmetic Dermatology</i> , <b>2021</b> , 20, 3364-3368	3.5	8
18	A Silent Attacker SARS-CoV-2 - A Review. <i>European Journal of Medical and Health Sciences</i> , <b>2020</b> , 2,	2	
17	Adverse Drug Reactions During COVID-19 Treatment. <i>Turkish Journal of Pediatric Disease</i> , 65-71		
16	Recomendaciones sobre el manejo en psoriasis y COVID-19: opini3n de expertos. <i>Revista De La Asociaci3n Colombiana De Dermatolog3a Y Cirug3a Dermatol3gica</i> , <b>2020</b> , 28, 138-147	0.1	
15	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. <i>Drug Development Research</i> , <b>2021</b> ,	5.1	3
14	Changes in the clinical course of psoriasis post-COVID-19: a clinical case series. <i>Al?manah Klini?askoj Mediciny</i> , <b>2021</b> , 49, 550-557	0.2	
13	Erythroderme Psoriasis nach COVID-19-Erkrankung. <i>Hautnah</i> , 1	0.2	
12	The impact of COVID-19 pandemic on the diagnostic distribution in dermatology outpatient clinic. <i>Journal of Biotechnology and Strategic Health Research</i> ,		
11	Repurposing Drugs for the Treatment of COVID-19. <i>Journal of Biotechnology and Bioindustry</i> , <b>2021</b> , 9, 9-15	0.1	
10	Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic.. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	
9	Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 812010	4.9	3
8	Biologics for Psoriasis During the COVID-19 Pandemic.. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 759568	4.9	2
7	[Erythrodermic psoriasis after COVID-19].. <i>Hautarzt</i> , <b>2021</b> , 73, 156	1.1	0
6	Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.. <i>Journal of Clinical and Aesthetic Dermatology</i> , <b>2021</b> , 14, 41-44	1.2	
5	Erythrodermic psoriasis in post-coronavirus disease 2019 patient.. <i>Asia Pacific Allergy</i> , <b>2022</b> , 12, e16	1.9	0
4	First-Trimester Impetigo Herpetiformis Leads to Stillbirth: A Case Report.. <i>Dermatology and Therapy</i> , <b>2022</b> ,	4	0

3	Safety of Short-Term Treatments with Oral Chloroquine and Hydroxychloroquine in Patients with and without COVID-19: A Systematic Review. <i>Pharmaceuticals</i> , <b>2022</b> , 15, 634	5.2	1
2	Examination of Cutaneous Changes Among Patients Following SARS-CoV-2 Infection. <i>Cureus</i> , <b>2022</b> ,	1.2	
1	Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study. <b>2022</b> ,		0